No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GOSS240719C500
- 0.54
- +0.24+80.00%
15min DelayClose Jul 5 16:00 ET
0.54High0.54Low
0.54Open0.30Pre Close1 Volume109 Open Interest0.50Strike Price54.00Turnover0.00%IV-3.70%PremiumJul 19, 2024Expiry Date0.58Intrinsic Value100Multiplier14DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.27Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Oppenheimer initiated coverage on Gossamer Bio Inc (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9. Gossamer Bio is focused on developing
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in
Express News | Gossamer Bio Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $9
Express News | Gossamer Bio Shares Are Trading Higher After Oppenheimer Initiated Coverage With an Outperform Rating and a Price Target of $9
Gossamer Bio Initiated at Outperform by Oppenheimer
Gossamer Bio Initiated at Outperform by Oppenheimer
Express News | Oppenheimer Initiates Coverage On Gossamer Bio With Outperform Rating, Announces Price Target of $9
Comments
$Gossamer Bio(GOSS.US$
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
• Oppenheimer has initiated Gossamer Bio at outperform expressing optimism on seralutinib, its inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension (PAH).
• The firm has a $9 price target (~984% upside based on June 24 close).
• Analyst Andreas Argyrides said that the candidate's safety and efficacy profile makes it "a preferred choice among severe PAH patients who are not ad...
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
• Oppenheimer has initiated Gossamer Bio at outperform expressing optimism on seralutinib, its inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension (PAH).
• The firm has a $9 price target (~984% upside based on June 24 close).
• Analyst Andreas Argyrides said that the candidate's safety and efficacy profile makes it "a preferred choice among severe PAH patients who are not ad...
3
$Gossamer Bio(GOSS.US$ Officer Hasnain Faheem purchased 372K shares of common stock on Jun 21, 2024 at an average price of $0.6728 for a total value of $250.28K.
5
$Gossamer Bio(GOSS.US$ Hold tight one dollar soon
1
$Gossamer Bio(GOSS.US$ Gossamer Bio Inc: $396 Mln in Cash, Cash Equivalents & Marketable Securities, as of March 31, 2024! Enough to fund operations into Q1 2027![]()
2
7
Read more